UNICREDIT BANK/CALL/ELI LILLY & CO/1350/0.1/14.01.26 | Real-time BOERSE MUENCHEN 03:41:48 2024-05-17 pm EDT | ||
| 2.4 EUR | -2.44% |
|
| Current month | -10.78% | ||
| 1 month | +3.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.4 | -2.44% |
| 24-05-16 | 2.46 | -1.60% |
| 24-05-15 | 2.5 | +13.12% |
| 24-05-14 | 2.21 | +0.45% |
| 24-05-13 | 2.2 | -6.78% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4PEA |
| ISIN | DE000HD4PEA9 |
| Date issued | 2024-04-16 |
| Strike | 1,350 $ |
| Maturity | 2026-01-14 (605 Days) |
| Parity | 10 : 1 |
| Emission price | 2.75 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.87 € |
|---|---|
| Lowest since issue | 1.95 € |
| Spread | 0.12 € |
| Spread % | 4.96% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Warrants
- Warrant
